Therapeutic Asset Ratings

388 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
gsk1120212 Non-small Cell Lung Cancer	Novartis Pharmaceuticals	P4	B (58)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) Hereditary Periodic Fever Syndromes	Novartis Pharmaceuticals	P3	B (58)
Keyhole Limpet Hemocyanin Multiple Sclerosis, Relapsing-Remitting	Novartis Pharmaceuticals	P3	B (58)
Pelabresib Solid Tumor	Novartis Pharmaceuticals	P3	B (58)
FULVESTRANT Castration-Resistant Prostate Carcinoma	Novartis Pharmaceuticals	P2	B (58)
gsk1120212 Colorectal Carcinoma	Novartis Pharmaceuticals	P2	B (58)
Letrozole Colorectal Carcinoma	Novartis Pharmaceuticals	P2	B (58)
Letrozole Metastatic Prostate Cancer	Novartis Pharmaceuticals	P2	B (58)
Keyhole Limpet Hemocyanin Relapsing Multiple Sclerosis	Novartis Pharmaceuticals	P3	B (57)
Ibrutinib Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals	P2	B (57)
Letrozole Melanoma	Novartis Pharmaceuticals	P2	B (56)
Letrozole Castration-Resistant Prostate Carcinoma	Novartis Pharmaceuticals	P2	CCC (55)
Letrozole Colorectal Neoplasms	Novartis Pharmaceuticals	P2	CCC (55)
LEUPROLIDE Melanoma	Novartis Pharmaceuticals	P2	CCC (55)
Onfasprodil Major Depressive Disorder	Novartis Pharmaceuticals	P2	CCC (55)
Ribociclib Carcinoma, Non-Small Cell Lung	Novartis Pharmaceuticals	P1/2	CCC (55)
aaa817 Prostate Cancer	Novartis Pharmaceuticals	P3	CCC (54)
Ociperlimab Non Small Cell Lung Cancer	Novartis Pharmaceuticals	P3	CCC (54)
Pelabresib Hematologic Malignancy	Novartis Pharmaceuticals	P3	CCC (54)
Siponimod Multiple Sclerosis	Novartis Pharmaceuticals	P3	CCC (54)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)	Novartis Pharmaceuticals	P2	CCC (54)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) TNF Receptor Associated Periodic Syndrome (TRAPS)	Novartis Pharmaceuticals	P2	CCC (54)
Branaplam Early Manifest Huntington Disease	Novartis Pharmaceuticals	P2	CCC (53)
Cyclophosphamide Scleroderma, Diffuse	Novartis Pharmaceuticals	P2	CCC (53)
DOTA-PABZA-DIG-DPHE-GLN-TRP-ALA-VAL-GLY-HIS-NHCH(CH2CH(CH3)2)2 Breast Cancer	Novartis Pharmaceuticals	P2	CCC (53)

Showing 101 to 125 of 388 assets

PreviousPage 5 of 16Next